Key points are not available for this paper at this time.
Because Becker muscular dystrophy (BMD) is a heterogeneous disease and only few studies have evaluated adult patients, it is currently still unclear which outcome measures should be used in future clinical trials.
Wel et al. (2024) studied this question.